E5104. Radiofrequency Ablation for Solitary T1N0M0 Papillary Thyroid Carcinoma in the Danger Triangle Area: A Preliminary Study
  1. Wu Songsong; No Affiliation
  2. Danling Zhang; No Affiliation
  3. Sheng Chen; No Affiliation
  4. Yang Jian Chuan; No Affiliation
  5. Hong Zhi Liang; No Affiliation
This study aims to evaluate the feasibility, efficacy, and safety of radiofrequency ablation (RFA) for solitary T1N0M0 papillary thyroid carcinoma (PTC) in the danger triangle area.

Materials and Methods:
Ninety-four participants (mean age, 44.45 ± 13.08; 73 women) with solitary T1N0M0 PTC in the danger triangle area who underwent percutaneous RFA at a single hospital from January 2020 to April 2022 were retrospectively analyzed. Ablation involved sufficient paratracheal fluid isolation with low-power, short-electrode (5 mm working electrode). Tumor size changes at different time points after RFA, technical success rates, tumor disappearance, disease progression, and complications were recorded and compared.

Contrast-enhanced ultrasonography showed 100% success rate with complete tumor ablation in all patients. Post-ablationPostablation, the maximum diameter and volume of the ablation zone increased at first and third month (P<p < 0.001), followed by a gradual decrease in size at 6, 9, 12, and 18 months, without significant difference by the 6th month. Tumor disappearance rate was 62.7% (59/94), with higher rates in the T1a group compared to the T1b group (70% [56/80] VS21vs 21.4% [3/14], p< < 0.001). There were no local recurrences. The incidence of new lesions and LNM was 3.2% (3/94), limited to the T1a subgroup. Further ablation was successfully applied to all new lesions and LMN. Light voice changes were the only complication, with a rate of 3.2% (3/94), resolved within 4 months after RFA.

Sufficient paratracheal fluid isolation combined with a low-power, short-electrode radiofrequency ablation strategy is a safe and effective method for treating solitary T1N0M0 PTC in the danger triangle area.